/Charles%20River%20Laboratories%20International%20Inc_%20logo-%20by%20IgorGolovniov%20via%20Shutterstock.jpg)
With a market cap of $6.7 billion, Charles River Laboratories International, Inc. (CRL) is a global, early-stage contract research organization supporting drug discovery and development. Through its three segments - Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions, the company provides essential products, services, and testing solutions to pharmaceutical, biotechnology, government, and academic clients worldwide.
CRL is expected to release its fiscal Q1 2025 earnings results before the market opens on Wednesday, May 7. Ahead of this event, analysts expect the company to report an adjusted profit of $2.06 per share, down 9.3% from $2.27 per share in the prior year's quarter. However, it has surpassed Wall Street's bottom-line estimates in the past four quarters.
